Variable Inhibition of DNA Unwinding Rates Catalyzed by the SARS-CoV-2 Helicase Nsp13 by Structurally Distinct Single DNA Lesions.

Publication date: Jul 19, 2024

The SARS-CoV-2 helicase, non-structural protein 13 (Nsp13), plays an essential role in viral replication, translocating in the 5′ → 3′ direction as it unwinds double-stranded RNA/DNA. We investigated the impact of structurally distinct DNA lesions on DNA unwinding catalyzed by Nsp13. The selected lesions include two benzo[a]pyrene (B[a]P)-derived dG adducts, the UV-induced cyclobutane pyrimidine dimer (CPD), and the pyrimidine (6-4) pyrimidone (6-4PP) photolesion. The experimentally observed unwinding rate constants (k) and processivities (P) were examined. Relative to undamaged DNA, the k values were diminished by factors of up to ~15 for B[a]P adducts but only by factors of ~2-5 for photolesions. A minor-groove-oriented B[a]P adduct showed the smallest impact on P, which decreased by ~11% compared to unmodified DNA, while an intercalated one reduced P by ~67%. However, the photolesions showed a greater impact on the processivities; notably, the CPD, with the highest k value, exhibited the lowest P, which was reduced by ~90%. Our findings thus show that DNA unwinding efficiencies are lesion-dependent and most strongly inhibited by the CPD, leading to the conclusion that processivity is a better measure of DNA lesions’ inhibitory effects than unwinding rate constants.

Open Access PDF

Concepts Keywords
Benzoapyrene 6–4PP
Dna COVID-19
Nsp13 CPD
Smallest crosslinked thymine dimer
Viral DNA
DNA
DNA Damage
DNA Helicases
DNA Helicases
Humans
Kinetics
Methyltransferases
Methyltransferases
Nsp13 helicase
Nsp13 protein, SARS-CoV
processivity
protein–DNA interactions
RNA Helicases
RNA Helicases
SARS-CoV-2
SARS-CoV-2
SF1 helicase
unwinding
UV photolesions
Viral Nonstructural Proteins
Viral Nonstructural Proteins

Semantics

Type Source Name
pathway KEGG Viral replication
drug DRUGBANK Tropicamide
drug DRUGBANK Ademetionine
disease VO USA
disease MESH genome stability
disease IDO replication
disease IDO host
disease MESH COVID 19 pandemic
drug DRUGBANK ATP
drug DRUGBANK Coenzyme M
disease VO effective
drug DRUGBANK Guanine
drug DRUGBANK Thymine
drug DRUGBANK Aminohippuric acid
drug DRUGBANK Tromethamine
drug DRUGBANK Potassium Chloride
drug DRUGBANK Glycerin
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Activated charcoal
disease MESH dissociation
disease IDO process
disease VO time
disease MESH DNA Damage

Original Article

(Visited 3 times, 1 visits today)